Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Risk of Gleason Score 3 + 4 = 7 prostate cancer upgrading at radical prostatectomy is significantly reduced by target biopsy compared to standard biopsy technique.

De Luca S, Fiori C, Bollito E, Garrou D, Aimar R, Cattaneo G, De Cillis S, Manfredi M, Tota D, Massa F, Passera R, Porpiglia F.

Minerva Urol Nefrol. 2019 Oct 10. doi: 10.23736/S0393-2249.19.03367-8. [Epub ahead of print]

PMID:
31619029
2.

Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score.

Porpiglia F, DE Luca S, Passera R, Manfredi M, Mele F, Bollito E, DE Pascale A, Cossu M, Aimar R, Veltri A.

Anticancer Res. 2016 Sep;36(9):4833-9.

PMID:
27630337
3.

Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.

Flood TA, Schieda N, Keefe DT, Breau RH, Morash C, Hogan K, Belanger EC, Mai KT, Robertson SJ.

Virchows Arch. 2016 Sep;469(3):313-9. doi: 10.1007/s00428-016-1981-2. Epub 2016 Jul 10.

PMID:
27394432
4.

Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.

Keefe DT, Schieda N, El Hallani S, Breau RH, Morash C, Robertson SJ, Mai KT, Belanger EC, Flood TA.

Virchows Arch. 2015 Oct;467(4):437-42. doi: 10.1007/s00428-015-1809-5. Epub 2015 Jul 31.

PMID:
26229020
5.

The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy.

Mannaerts CK, Kajtazovic A, Lodeizen OAP, Gayet M, Engelbrecht MRW, Jager GJ, Wijkstra H, de Reijke TM, Beerlage HP.

Urol Oncol. 2019 May;37(5):298.e1-298.e9. doi: 10.1016/j.urolonc.2019.01.005. Epub 2019 Jan 17.

PMID:
30660493
6.

Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.

Mannaerts CK, Gayet M, Verbeek JF, Engelbrecht MRW, Savci-Heijink CD, Jager GJ, Gielens MPM, van der Linden H, Beerlage HP, de Reijke TM, Wijkstra H, Roobol MJ.

Eur Urol Oncol. 2018 Jun;1(2):109-117. doi: 10.1016/j.euo.2018.02.010. Epub 2018 May 15.

PMID:
31100233
7.

The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer.

Fourcade A, Payrard C, Tissot V, Perrouin-Verbe MA, Demany N, Serey-Effeil S, Callerot P, Coquet JB, Doucet L, Deruelle C, Joulin V, Nonent M, Fournier G, Valeri A.

Scand J Urol. 2018 Jun;52(3):174-179. doi: 10.1080/21681805.2018.1438509. Epub 2018 Feb 20.

PMID:
29463177
8.

Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.

Alberts AR, Roobol MJ, Drost FH, van Leenders GJ, Bokhorst LP, Bangma CH, Schoots IG.

BJU Int. 2017 Oct;120(4):511-519. doi: 10.1111/bju.13836. Epub 2017 Apr 4.

9.

Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis.

Goel S, Shoag JE, Gross MD, Al Hussein Al Awamlh B, Robinson B, Khani F, Baltich Nelson B, Margolis DJ, Hu JC.

Eur Urol Oncol. 2019 Sep 4. pii: S2588-9311(19)30121-X. doi: 10.1016/j.euo.2019.08.001. [Epub ahead of print] Review.

PMID:
31492650
10.

Comparing Image-guided targeted Biopsies to Radical Prostatectomy Specimens for Accurate Characterization of the Index Tumor in Prostate Cancer.

Porpiglia F, DE Luca S, Checcucci E, Garrou D, Manfredi M, Mele F, Pecoraro A, Passera R, Bollito E, Fiori C.

Anticancer Res. 2018 May;38(5):3043-3047.

11.

Gleason score 3 + 4=7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen.

Huang CC, Kong MX, Zhou M, Rosenkrantz AB, Taneja SS, Melamed J, Deng FM.

Am J Surg Pathol. 2014 Aug;38(8):1096-101. doi: 10.1097/PAS.0000000000000235.

PMID:
24832163
12.

Risk of upgrading from prostate biopsy to radical prostatectomy pathology: Is magnetic resonance imaging-guided biopsy more accurate?

Xu N, Wu YP, Li XD, Lin MY, Zheng QS, Chen SH, Li JF, Wei Y, Xue XY.

J Cancer. 2018 Sep 8;9(19):3634-3639. doi: 10.7150/jca.26791. eCollection 2018.

13.

Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.

Tilki D, Schlenker B, John M, Buchner A, Stanislaus P, Gratzke C, Karl A, Tan GY, Ergün S, Tewari AK, Stief CG, Seitz M, Reich O.

Urol Oncol. 2011 Sep-Oct;29(5):508-14. doi: 10.1016/j.urolonc.2009.07.003. Epub 2009 Oct 17.

PMID:
19837614
14.

PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.

Zhai L, Fan Y, Sun S, Wang H, Meng Y, Hu S, Wang X, Yu W, Jin J.

Scand J Urol. 2018 Oct - Dec;52(5-6):333-339. doi: 10.1080/21681805.2018.1545799.

PMID:
30895901
15.

Prostate Cancers Detected by Magnetic Resonance Imaging-Targeted Biopsies Have a Higher Percentage of Gleason Pattern 4 Component and Are Less Likely to Be Upgraded in Radical Prostatectomies.

Zhao Y, Deng FM, Huang H, Lee P, Lepor H, Rosenkrantz AB, Taneja S, Melamed J, Zhou M.

Arch Pathol Lab Med. 2019 Jan;143(1):86-91. doi: 10.5858/arpa.2017-0410-OA. Epub 2018 Jul 2.

PMID:
29965785
16.

Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer.

Stabile A, Dell'Oglio P, Soligo M, De Cobelli F, Gandaglia G, Fossati N, Esposito A, Brembilla G, Karnes RJ, Montorsi F, Briganti A.

Eur Urol Oncol. 2019 Jun 13. pii: S2588-9311(19)30073-2. doi: 10.1016/j.euo.2019.05.006. [Epub ahead of print]

PMID:
31204312
17.

Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis.

Sidana A, Watson MJ, George AK, Rastinehad AR, Vourganti S, Rais-Bahrami S, Muthigi A, Maruf M, Gordetsky JB, Nix JW, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA.

Urol Oncol. 2018 Jul;36(7):341.e1-341.e7. doi: 10.1016/j.urolonc.2018.04.002. Epub 2018 May 10.

PMID:
29753548
18.

The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men.

Kongnyuy M, Sidana A, George AK, Muthigi A, Iyer A, Fascelli M, Kadakia M, Frye TP, Ho R, Mertan F, Minhaj Siddiqui M, Su D, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA.

Urol Oncol. 2016 Jun;34(6):254.e15-21. doi: 10.1016/j.urolonc.2015.12.018. Epub 2016 Feb 20.

PMID:
26905304
19.

Gleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry - Victoria.

Evans SM, Patabendi Bandarage V, Kronborg C, Earnest A, Millar J, Clouston D.

Prostate Int. 2016 Dec;4(4):145-151. Epub 2016 Aug 3.

20.

Is small prostate volume a predictor of Gleason score upgrading after radical prostatectomy?

Chung MS, Lee SH, Lee DH, Chung BH.

Yonsei Med J. 2013 Jul;54(4):902-6. doi: 10.3349/ymj.2013.54.4.902.

Supplemental Content

Support Center